5 Stocks Trading Under $10 That Have Huge Upside Potential

Lee Jackson

This is a solid value play now and a great dividend play as well. Ford Motor Co. (NYSE: F) is one of the world’s largest vehicle producers, with over 6 million units manufactured/sold globally. The company has made significant progress executing on its One Ford plan and delivering best-in-class vehicles. It also remains committed to positioning itself well within the evolving auto industry through balanced investments across electrification, autonomy and mobility services.

The company posted light second-quarter numbers and lowered the overall 2018 outlook. Some analysts on Wall Street are concerned about a lack of direction at Ford, and more recently the postponement of its September analysts day. Despite the setbacks, the F-100 remains the best-selling truck in the United States.

Ford shareholders are paid an outstanding 6.31% dividend. The Jefferies Buy rating is accompanied by a $13.40 price target. The posted consensus target is $11.05, and the shares closed at $9.55 on Friday.

Kosmos Energy

This is a solid energy exploration and production play. Kosmos Energy Ltd. (NYSE: KOS) is a conventional oil and gas E&P company focused on the Atlantic margin and on unlocking new hydrocarbon systems and growing and maturing discovered basins through follow-on exploration success, development and production.

Although many of its peers have scaled back exploration, Kosmos believes this is the best route to generating value, seeking to replicate its discovery and development of the Jubilee field in Ghana.

Jefferies has a Buy rating and a $9.50 price objective here. The consensus target was last seen at $9.29, and the shares closed trading on Friday at $7.88.

Rigel Pharmaceuticals

The Jefferies team has covered this company for years, and the low price makes it an attractive target. Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) is engaged in the discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases.

The company’s pioneering research focuses on signaling pathways that are critical to disease mechanisms. Its clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase inhibitor, in a number of indications.

The $7 Jefferies price target compares to the $7.92 consensus target and to the most recent close at $2.62 a share.

These are five stocks for aggressive accounts that look to get share-count leverage on companies that have sizable upside potential. While they are not suited for all investors, these are not penny stocks with absolutely no track record or liquidity, and major Wall Street firms have research coverage on all of them.